Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NEK2 | P51955 | 2/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939352 | 0.91 | CYP3A4 (0.61) | CYP3A4KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1938838 | 0.88 | CYP3A4 (0.64) | CYP3A4KDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1938708 | 0.86 | CYP3A4 (0.67) | CYP3A4KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL1939604 | 0.84 | CYP3A4 (0.64) | CYP3A4KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1938820 | 0.83 | CYP3A4 (0.70) | CYP3A4KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1939659 | 0.82 | CYP3A4 (0.55) | CYP3A4KDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1938565 | 0.82 | CYP3A4 (0.71) | CYP3A4SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL1939040 | 0.82 | CYP3A4 (0.71) | CYP3A4KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12363686 | 0.82 | CYP3A4 (0.64) | CYP3A4KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1938861 | 0.81 | CYP3A4 (0.73) | CYP3A4KDM4ESMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | claimed |
| EP-2331523-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2011-06-15 | — | — | EP | claimed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | claimed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | CYP3A4 1871/4885KDM4E 1624/4885SMN1; SMN2 4623/4885 |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | CYP3A4 1871/4885KDM4E 1624/4885SMN1; SMN2 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.